This website uses cookies to enhance your browsing experience, improve site performance, and gather analytics. By selecting 'Accept,' you consent to these cookies as described in our Privacy Policy.

HomeBrowseAboutFAQs
Log In
Sign Up
Urinary Tract Infections

Efficacy and Mechanism of Action of Methenamine Hippurate (Hiprex™) in Women With Recurring Urinary Tract Infections.

Sponsored by University of Texas Southwestern Medical Center

About this trial

Last updated 2 years ago

Study ID

STU-2020-0725

Status

Recruiting

Type

Interventional

Phase

Phase 4

Placebo

No

Accepting

18-75 Years
50 to 85 Years
Female
Female

Not accepting

Not accepting
Healthy Volunteers

Trial Timing

Ended 2 years ago

What is this trial about?

The purpose of this study is to measure the concentration of formaldehyde in the urine of women with recurrent urinary tract infections on Hiprex; and then, assuming its urinary presence is confirmed at the proper acid urinary pH, evaluate if such a therapy has favorable effects in decreasing the rate of recurrent urinary tract infections over time.

What are the participation requirements?

Yes

Inclusion Criteria

1. Female

2. Age 50 - 85

3. Have RUTIs (at least 2 UTIs within the past 6 months or 3 within the past year) -

No

Exclusion Criteria

1. Being on antibiotics at baseline (i.e. suppressive therapy or antibiotic therapy for urinary or non-urinary infections)

2. Neurogenic bladder condition

3. Using urinary catheters (including Foley catheter, intermittent catheterization, and suprapubic catheter)

4. Uncontrolled diabetes (HbA1c > 9)

5. Chronic renal failure defined as serum creatinine > 1.5 mg/dL

6. History of liver disease

7. Patients from out of town, in whom follow-up will not be possible

8. Pregnancy

9. Allergy to Hiprex

10. Inability to take Hiprex reliably at home, such as having psychosis, dementia, or swallowing disorders

11. Non-English speakers -

Locations

Location

Status

Recruiting